Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain

Figure 1:

Study PTVA-OA-001: WOMAC (11-point NRS) Question A1 Change from Baseline to Week 12: Pooled Placebo, Pooled RTX, RTX 12.5 mcg
Study PTVA-OA-001: WOMAC (11-point NRS) Question A1 Change from Baseline to Week 12: Pooled Placebo, Pooled RTX, RTX 12.5 mcg
Study PTVA-OA-001: WOMAC (11-point NRS) Question A1 Change from Baseline to Week 12: Pooled Placebo, Pooled RTX, RTX 12.5 mcg

Figure 2:

Study PTVA-OA-001 WOMAC A (pain) plus WOMAC C (function), using the 11-point NRS format, from baseline to Week 12 for Pooled Placebo, Pooled RTX, RTX 12.5 mcg
Study PTVA-OA-001 WOMAC A (pain) plus WOMAC C (function), using the 11-point NRS format, from baseline to Week 12 for Pooled Placebo, Pooled RTX, RTX 12.5 mcg
Study PTVA-OA-001 WOMAC A (pain) plus WOMAC C (function), using the 11-point NRS format, from baseline to Week 12 for Pooled Placebo, Pooled RTX, RTX 12.5 mcg
  • Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled.

  • No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months post-administration. The study is scheduled to complete the last patient follow-up (1 year) in 1Q2021.

  • Dose of

Read More